BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Escobar C, Martí-almor J, Pérez Cabeza A, Martínez-zapata MJ. Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. Revista Española de Cardiología 2019;72:305-16. [DOI: 10.1016/j.recesp.2018.02.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Barrios V, Escobar C, Gómez-Doblas JJ, Fernández-Dueñas J, Garrido RR, Rodríguez JP, Sánchez JU, Arellano-Rodrigo E, Donado E; RE-SONANCE investigator’s group. Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists. J Comp Eff Res 2020;9:615-25. [PMID: 32469278 DOI: 10.2217/cer-2020-0001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sanchis J, Avanzas P, Filgueiras-rama D, García-pavía P, Sanchis L, del Río I. Nuevo equipo editorial, nuevas perspectivas. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2022.01.011] [Reference Citation Analysis]
3 Barón-Esquivias G, Roldán Rabadán I, García Quintana A, Cerezo Manchado JJ, Antorrena Miranda I, Gómez-Barrado JJ, Pérez Paredes M, Santas E, Pindado Rodríguez J, Muñoz-Robles JA, Oliver-Miñarro D, Santamaría A; investigators of ETNA AF Spain. Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry. Future Cardiol 2020;16:469-80. [PMID: 32228182 DOI: 10.2217/fca-2020-0024] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sanmartín M, Bellmunt S, Cosín-sales J, García-moll X, Riera-mestre A, Almendro-delia M, Hernández JL, Lozano F, Mazón P, Suarez Fernández C. Role of rivaroxaban in the prevention of atherosclerotic events. Expert Review of Clinical Pharmacology 2019;12:771-80. [DOI: 10.1080/17512433.2019.1637732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Escobar C, Camm AJ. Changing paradigms: from prevention of thromboembolic events to improved survival in patients with atrial fibrillation. Europace 2021;23:837-43. [PMID: 33221894 DOI: 10.1093/europace/euaa324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Fernández CS, Gullón A, Formiga F. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. J Comp Eff Res 2020;9:509-23. [PMID: 32329353 DOI: 10.2217/cer-2019-0197] [Reference Citation Analysis]
7 Sebastián OG, Fernández MI, Fernández RM, Bernal LP. Use of rivaroxaban in patients attending a hematology unit in clinical practice. Future Cardiol 2019;15:347-53. [PMID: 31468995 DOI: 10.2217/fca-2018-0086] [Reference Citation Analysis]
8 Deitelzweig S, Bergrath E, di Fusco M, Kang A, Savone M, Cappelleri JC, Russ C, Betts M, Cichewicz A, Schaible K, Tarpey J, Fahrbach K. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. Future Cardiol 2022. [PMID: 35360925 DOI: 10.2217/fca-2021-0120] [Reference Citation Analysis]
9 Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Navarro-almenzar B, Cerezo-manchado JJ, Caro-martinez C, García-candel F, Flores Blanco PJ, Ruiz GE, Andreu Cayuelas JM, Montoya FA, Cascales A, Lova Navarro A, García Alberola A, Andrés Pascual Figal D, Bailen Lorenzo JL, Manzano-fernández S. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry. Current Medical Research and Opinion 2019;35:2035-41. [DOI: 10.1080/03007995.2019.1647735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Freixa-Pamias R, Blanch Gràcia P, Rodríguez Latre ML, Basile L, Sanchez Chamero P, Gomez-Choco M, Armario P, Martínez-Rubio A, Lupón J; Working Group for coordination between Cardiology & Primary Care, Barcelona, Spain. Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke. Curr Med Res Opin 2021;37:357-65. [PMID: 33326304 DOI: 10.1080/03007995.2020.1865892] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ferreira-gonzález I, Sánchez-recalde Á, Abu-assi E, Arias MÁ, Gallego P, del Río I. Revista Española de Cardiología: anuario de 2019. Revista Española de Cardiología 2020;73:410-7. [DOI: 10.1016/j.recesp.2020.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Escobar Cervantes C, Barrios Alonso V. Direct oral anticoagulants today. Med Clin (Barc) 2021;157:238-40. [PMID: 34353625 DOI: 10.1016/j.medcli.2021.07.001] [Reference Citation Analysis]